VivoSeq
Other

Methotrexate

0

Pipeline Programs↗

11

Active Trials↗

18

Companies Involved↗

Methotrexate is an early-stage landscape with 0 programs across 18 companies. The most active players are Bristol-Myers Squibb, Pfizer, Roche.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalA

Antares Pharma Inc.

0 programs

PreclinicalG

Gynecologic Oncology Group

0 programs

PreclinicalVertex Pharmaceuticals logo

Vertex Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

91

clinical trials

Completed54 · 59%
Unknown status15 · 16%
Terminated10 · 11%
Recruiting6 · 7%
Active, not recruiting2 · 2%
Not yet recruiting2 · 2%
Other2 · 2%

Clinical Trials

Trial Activity

91 trials

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Recruiting·FFudan University·Phase 2·NCT05257018·83 enrolled
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT05102448·76 enrolled
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
Recruiting·PProtalix·Phase 2·NCT07280156·150 enrolled
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Recruiting·—·Phase 2/3·NCT05057130·50 enrolled
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)
Recruiting·TTongji Hospital·Phase 2·NCT07350850·110 enrolled
Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment
Recruiting·HHospices Civils de Lyon·Phase 1/2·NCT04396223·26 enrolled
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
Active, not recruiting·—·N/A·NCT04562558·228 enrolled
Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects
Active, not recruiting·SSeoul National University Bundang Hospital·Phase 1·NCT07196449·12 enrolled
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
Not yet recruiting·Otsuka logoOtsuka·Phase 1·NCT07446400·48 enrolled
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
Not yet recruiting·RRuijin Hospital·Phase 2·NCT06901999·23 enrolled
A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA.
Enrolling by invitation·—·N/A·NCT06281184·108 enrolled
Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children with Recurrent Posterior Fossa Brain Tumors
Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT02905110·3 enrolled
Co-Administration Of Methotrexate And CP-690,550
Completed·Pfizer logoPfizer·Phase 1·NCT01745055·12 enrolled
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
Completed·Roche logoRoche·Phase 3·NCT01855789·718 enrolled
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia
Completed·GGynecologic Oncology Group·Phase 3·NCT00003702·240 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)